% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fox:281511,
      author       = {Fox, Nick C and Belder, Christopher and Ballard, Clive and
                      Kales, Helen C and Mummery, Catherine and Caramelli, Paulo
                      and Ciccarelli, Olga and Frederiksen, Kristian S and
                      Gomez-Isla, Teresa and Ismail, Zahinoor and Paquet, Claire
                      and Petersen, Ronald C and Perneczky, Robert and Robinson,
                      Louise and Sayin, Ozge and Frisoni, Giovanni B},
      title        = {{T}reatment for {A}lzheimer's disease.},
      journal      = {The lancet},
      volume       = {406},
      number       = {10510},
      issn         = {0140-6736},
      address      = {London [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DZNE-2025-01132},
      pages        = {1408 - 1423},
      year         = {2025},
      abstract     = {Over the last three decades, the evidence on how to best
                      treat the cognitive and non-cognitive symptoms of patients
                      with Alzheimer's disease has increased. Although these
                      pharmacological and non-pharmacological strategies have
                      significantly improved health outcomes for patients with
                      Alzheimer's disease, many lack stringent evidence of
                      efficacy. In this second paper of the Series, we provide
                      practical and realistic advice on how to prioritise
                      pharmacological and non-pharmacological strategies to
                      ameliorate cognitive impairment and behavioural and
                      psychological symptoms of dementia. In this clinical
                      environment, dementia specialists are faced with the
                      challenge of holistically integrating the much anticipated
                      and, in some respects, controversial anti-β amyloid
                      monoclonal antibodies. Here, we present the current approval
                      scenario of monoclonal antibodies, our view on how they
                      might further contribute to improve patients' quality of
                      life, and how they could be seamlessly integrated with
                      existing best care options.},
      subtyp        = {Review Article},
      keywords     = {Humans / Alzheimer Disease: drug therapy / Alzheimer
                      Disease: therapy / Antibodies, Monoclonal: therapeutic use /
                      Quality of Life / Amyloid beta-Peptides: antagonists $\&$
                      inhibitors / Amyloid beta-Peptides: immunology / Antibodies,
                      Monoclonal, Humanized: therapeutic use / Antibodies,
                      Monoclonal (NLM Chemicals) / Amyloid beta-Peptides (NLM
                      Chemicals) / Antibodies, Monoclonal, Humanized (NLM
                      Chemicals)},
      cin          = {AG Dichgans},
      ddc          = {610},
      cid          = {I:(DE-2719)5000022},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40997839},
      doi          = {10.1016/S0140-6736(25)01329-7},
      url          = {https://pub.dzne.de/record/281511},
}